Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

Oxidation resistance of LDL is correlated with vitamin E status in beta-thalassemia intermedia.

1998

The alteration of the oxidant/antioxidant balance may affect the susceptibility of low density lipoproteins (LDL) to oxidation in haemolytic disorders such as thalassemia. Thirty patients affected by beta-thalassemia intermedia were examined, and compared with age-matched healthy controls. The mean amount of vitamin E in the thalassemic LDL was lower than control (p0.0001), either when it was calculated on the base of LDL protein (61% decrease) or cholesterol (25% decrease). The LDL resistance to Cu2+-induced oxidation, evaluated as the length of the lag phase before the onset of conjugated diene (CD) lipid hydroperoxide production, was 20% lower than control. Other parameters of LDL suscep…

Hemolytic anemiaAdultMalemedicine.medical_specialtyAntioxidantmedicine.medical_treatmentThalassemiaOxidative phosphorylationmedicine.disease_causeLipid peroxidationchemistry.chemical_compoundInternal medicinemedicineHumansVitamin ECholesterolVitamin Ebeta-ThalassemiaMiddle Agedmedicine.diseaseLipoproteins LDLOxidative StressEndocrinologyCholesterolchemistryRegression Analysislipids (amino acids peptides and proteins)FemaleLipid PeroxidationCardiology and Cardiovascular MedicineOxidation-ReductionOxidative stressFollow-Up StudiesAtherosclerosis
researchProduct

Hepatic lipase and lipoprotein lipase are affected by combined estrogen+progestin hormone therapy

2004

Hepatic lipase lipoprotein lipase estrogen progestin therapy
researchProduct

Prevalence, risk factor burden, and severity of coronary artery disease in patients with heterozygous familial hypercholesterolemia hospitalized for …

2019

Individuals with heterozygous familial hypercholesterolemia (FH) are at high risk of early myocardial infarction (MI). However, coronary artery disease (CAD) burden of FH remains not well described, especially for French patients.The objective of this study was to assess the prevalence of FH and severity of CAD from a large database of a French regional registry of acute MI.All consecutive patients hospitalized for an acute MI in a multicenter database from 2001 to 2017 were considered. FH was diagnosed using an algorithm adapted from the Dutch Lipid Clinic Network criteria. The prevalence and clinical features of FH and the severity of CAD were assessed.Among the 11,624 patients included i…

Heterozygotemedicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Myocardial InfarctionFamilial hypercholesterolemia030204 cardiovascular system & hematologySeverity of Illness IndexCohort StudiesHyperlipoproteinemia Type IICoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinePrevalenceInternal MedicinemedicineHumansIn patientRegistries030212 general & internal medicineMyocardial infarctionRisk factorAcute miLipid clinicAgedAged 80 and overNutrition and Dieteticsbusiness.industryCholesterol LDLMiddle AgedEzetimibemedicine.disease3. Good healthLarge cohortHospitalizationFranceHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular Medicinebusiness
researchProduct

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper fr…

2014

Item does not contain fulltext AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity of genetic defects and clinical phenotype of HoFH, and the availability of new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) critically reviewed available data with the aim of providing clinical guidance for the recognition and management of HoFH. METHODS AND RESULTS: Early diagn…

Homozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaVascular damage Radboud Institute for Health Sciences [Radboudumc 16]MipomersenLipoprotein apheresisGene FrequencyDiagnosisconsensuMedicineChildPhenotypic heterogeneityCiències de la salutAnticholesteremic AgentsHomozygoteCiencias de la saludPedigree3. Good healthEuropePhenotypeCardiovascular DiseasesPractice Guidelines as TopicBlood Component Removallipids (amino acids peptides and proteins)HipercolesterolèmiaHIPERCOLESTEROLEMIA (DIAGNÓSTICO)Cardiology and Cardiovascular MedicineLipoprotein apheresismedicine.medical_specialtyConsensusClinical UpdateEvinacumabReviewsguide line1102 Cardiovascular Medicine And Haematology1016-5169Diagnosis DifferentialHyperlipoproteinemia Type IIGenetic HeterogeneityArcus SenilisHomozygous familial hypercholesterolaemiaGeneticsXanthomatosisHumansGynecologybusiness.industryStatinsHealth sciencesCholesterol LDLAtherosclerosisEzetimibeLomitapideLiver TransplantationEarly DiagnosisCardiovascular System & HematologyHomozygous familial hypercholesterolaemia; consensus; guide lineMutationEuropean atherosclerosis societybusinessAterosclerosiEuropean Heart Journal
researchProduct

LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.

1997

Preliminary experience with the efficacy and safety of dextran sulfate cellulose low-density lipoprotein (LDL) apheresis for the treatment of a 4.5-year-old girl with homozygous familial hypercholesterolemia and coronary artery disease is reported. The decrease of the most atherogenic apolipoprotein B-containing lipoproteins, low-density lipoprotein (LDL) and lipoprotein(a) (Lp [a]), were in the ranges of 63.1-68.7%, and 52.5-58.6%, respectively. The child tolerated LDL apheresis without any clinically significant complications. Therefore, she was submitted to a long-term program of treatment at intervals of 15 days. The experience suggests the possibility of an early beginning of extracorp…

Homozygous Familial Hypercholesterolemiamedicine.medical_specialtyApolipoprotein BBiomedical EngineeringMedicine (miscellaneous)BioengineeringCoronary Disease4.5 years-old girlFamilial hypercholesterolemiaBiomaterialsHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineCoronary Heart DiseaseHumansHyperlipoproteinemia Type IIbiologybusiness.industryCholesterolHomozygoteGeneral MedicineLipoprotein(a)Low Density Lipoprotein (LDL) apheresis; 4.5 years-old girl; Homozygous Familial Hypercholesterolemia; Coronary Heart Diseasemedicine.diseaseLipoproteins LDLApheresisEndocrinologyCholesterolLow Density Lipoprotein (LDL) apheresischemistryLDL apheresisChild Preschoolbiology.proteinBlood Component Removallipids (amino acids peptides and proteins)FemalebusinessLipoproteinLipoprotein(a)Artificial organs
researchProduct

Mobilization of late-endosomal cholesterol is inhibited by Rab guanine nucleotide dissociation inhibitor

2000

AbstractCholesterol entering cells in low-density lipoproteins (LDL) via receptor-mediated endocytosis is transported to organelles of the late endocytic pathway for degradation of the lipoprotein particles. The fate of the free cholesterol released remains poorly understood, however. Recent observations suggest that late-endosomal cholesterol sequestration is regulated by the dynamics of lysobisphosphatidic acid (LBPA)-rich membranes [1]. Genetic studies have pinpointed a protein, Niemann–Pick C-1 (NPC-1), that is required for the mobilization of late-endosomal/lysosomal cholesterol by an unknown mechanism [2]. Here, we report the removal of accumulated cholesterol by overexpression of the…

HydrolasesEndosomeEndocytic cycleEndosomesCholesterol 7 alpha-hydroxylaseGeneral Biochemistry Genetics and Molecular BiologyCell Line03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHumansGuanine Nucleotide Dissociation Inhibitors030304 developmental biologyNiemann-Pick Diseases0303 health sciencesbiologyAgricultural and Biological Sciences(all)CholesterolBiochemistry Genetics and Molecular Biology(all)Reverse cholesterol transportCholesterol LDLEndocytosisRecombinant ProteinsCell biologyCholesterolchemistryBiochemistryHMG-CoA reductasebiology.proteinMonoglycerideslipids (amino acids peptides and proteins)RabLysophospholipidsLysosomesGeneral Agricultural and Biological Sciences030217 neurology & neurosurgeryLipoproteinCurrent Biology
researchProduct

Low Density Lipoprotein Receptor-related Protein (LRP) Interacts with Presenilin 1 and Is a Competitive Substrate of the Amyloid Precursor Protein (A…

2005

Presenilin 1 (PS1) is a critical component of the gamma-secretase complex, which is involved in the cleavage of several substrates including the amyloid precursor protein (APP) and the Notch receptor. Recently, the low density receptor-related protein (LRP) has been shown to be cleaved by a gamma-secretase-like activity. We postulated that LRP may interact with PS1 and tested its role as a competitive substrate for gamma-secretase. In this report we show that LRP colocalizes and interacts with endogenous PS1 using coimmunoprecipitation and fluorescence lifetime imaging microscopy. In addition, we found that gamma-secretase active site inhibitors do not disrupt the interaction between LRP an…

ImmunoprecipitationNotch signaling pathwayMice TransgenicBinding CompetitiveBiochemistryPresenilinCell LineSubstrate SpecificityRats Sprague-DawleyAmyloid beta-Protein PrecursorMiceEndopeptidasesmental disordersPresenilin-1Amyloid precursor proteinAnimalsAspartic Acid EndopeptidasesHumansBinding siteMolecular BiologyBrain ChemistryBinding SitesbiologyChemistryMembrane ProteinsCell BiologyRatsnervous system diseasesCell biologyTransmembrane domainBiochemistryMultiprotein ComplexesLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Amyloid Precursor Protein SecretasesAmyloid precursor protein secretaseLow Density Lipoprotein Receptor-Related Protein-1Journal of Biological Chemistry
researchProduct

RT-PCR and in situ hybridization analysis of apolipoprotein H expression in rat normal tissues

2006

In this study, by using different techniques (i.e. Northern blot hybridization, RT-PCR and Southern blot hybridization) on various normal rat tissues, we were able to identify liver, kidney, heart, small intestine, brain, spleen, stomach and prostate as tissues in which the ApoH gene is transcribed. Moreover, for some of these tissues, by in situ hybridization, we found a specific localization of apoH transcripts. For instance epithelial cells of the bile ducts in liver and of the proximal tubules in kidney are the major sites of apoH synthesis. Our data suggest that some of the different physiological roles proposed for apoH could correlate with its direct expression, while others could co…

In situ hybridizationBiologyß-2-glycoprotein I apoH antiphospholipid syndrome Fanconi syndromeKidneyGeneticsmedicineAnimalsHumansBeta 2-Glycoprotein ITissue DistributionRNA MessengerNorthern blotRats WistarCells CulturedIn Situ HybridizationGlycoproteinsSouthern blotReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingMyocardiumKidney metabolismGeneral MedicineMolecular biologySmall intestineRatsJejunumReal-time polymerase chain reactionmedicine.anatomical_structureLiverbeta 2-Glycoprotein IApolipoprotein H
researchProduct

Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells.

2014

Abstract Background Resistance of cancer cells towards chemotherapeutics represents a major cause of therapy failure. The objective of our study was to evaluate cellular defense strategies in response to the novel vacuolar H+-ATPase inhibitor, archazolid B. Experimental approach: The effects of archazolid B on T24 bladder carcinoma cells were investigated by combining “omics” technologies (transcriptomics (mRNA and miRNA) and proteomics). Free cholesterol distribution was determined by filipin staining using flow cytometry and fluorescence microscopy. Flow cytometry was performed for LDLR surface expression studies. Uptake of LDL cholesterol was visualized by confocal microscopy. SREBP acti…

IndolesCell SurvivalBiologyReal-Time Polymerase Chain ReactionBiochemistryFatty Acids Monounsaturatedchemistry.chemical_compoundCell Line TumormedicineHumansFluvastatinPharmacologyCholesterolReproducibility of ResultsMolecular biologySterolEndocytosisSterol regulatory element-binding proteinGene Expression Regulation NeoplasticLipoproteins LDLMicroRNAsThiazolesCell killingCholesterolchemistryReceptors LDLUrinary Bladder NeoplasmsDrug Resistance NeoplasmLDL receptorCancer celllipids (amino acids peptides and proteins)Sterol regulatory element-binding protein 2MacrolidesSterol Regulatory Element Binding Protein 1Fluvastatinmedicine.drugSterol Regulatory Element Binding Protein 2Biochemical pharmacology
researchProduct

Complement and atherosclerosis—united to the point of no return?

2012

Atherosclerosis is widely regarded as a chronic inflammatory disease that develops as a consequence of entrapment of oxidized low-density lipoprotein (LDL) in the arterial intima and its interaction with components of both innate and adaptive immunity. This article reviews the role of the complement system in the context of a different concept on atherogenesis. Arguments are forwarded in support of the contention that enzymatic and not oxidative modification of LDL is the prerequisite for transforming the lipoprotein into a moiety that is recognized by the innate immune system. In a departure from general wisdom, it is proposed that these processes are initially not pathological. To the con…

InflammationInnate immune systemClinical BiochemistryContext (language use)InflammationComplement System ProteinsGeneral MedicineBiologyAtherosclerosisAcquired immune systemComplement systemLipoproteins LDLC-Reactive ProteinCholesterolImmune systemImmunologymedicineHumansMacrophagemedicine.symptomComplement ActivationFoam CellsFoam cellClinical Biochemistry
researchProduct